Objective: A combined thyroid transcription factor 1 (TTF-1) and Napsin A double stain has been shown to be useful in the diagnosis of adenocarcinoma (ADC). This study compares differences in double staining patterns among vendor antibodies (Leica, Dako, and Biocare). Study Design: The cohorts included 35 FNA cell blocks of lung ADC and 24 cell blocks of lung squamous cell carcinoma (SqCCA). Double-staining immunohistochemistry was performed with TTF-1 as a brown nuclear stain and Napsin A as a red cytoplasmic stain, using three sets of double stains. Additionally, FISH expression was performed on SqCCAs with aberrant TTF-1 expression. Results: The sensitivity for the double stains ranged from 40 to 74%, while the specificity ranged from 88 to 96%. Two Leica TTF-1-positive SqCCAs also showed low-level amplification by FISH assay not seen in the TTF-1-negative control SqCCAs. Conclusion: The use of Dako TTF-1 antibody paired with Leica Napsin A antibody as a double stain yielded the best results for diagnosing ADC; additionally, the Leica Napsin A-only staining results had the highest positive predictive value at 97%. Both Dako and Biocare antibodies expressed less staining of SqCCAs than Leica staining.

Keywords:
Thyroid transcription factor 1, Napsin A, Lung cancer, Fine-needle aspiration, Immunohistochemistry
1.
Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y: The new World Health Organization Classification of lung tumours. Eur Respir J 2001;18:1059–1068.
2.
Travis WD: Pathology of lung cancer. Clin Chest Med 2002;23:65–81.
3.
American Cancer Society: Cancer Facts & Figures 2004. 2005. http://www.cancer.org/docroot/STT/stt_0_2004.asp?sitearea=SST&level=1.
4.
Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244–285.
5.
Hirsch FR, Speafico A, Novello S, et al: The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3:1468–1481.
6.
Asami K, Koizumi T, Hirai K, et al: Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group Study. Clin Lung Cancer 2011;12:387–392.
7.
Reck M, Barlesi F, Crino L, et al: Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 2012;23:1111–1120.
8.
Hecht JL, Pinkus JL, Weinstein LJ, Pinkus GS: The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol 2001;116:483–488.
9.
Suzuki A, Shijubo N, Yamada G, et al: Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract 2005;201:579–586.
10.
Fatima N, Cohen C, Lawson D, Siddiqui MT: TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol 2011;119:127–133.
11.
Travis WD, Rekhtman N, Riley GJ, et al: Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411–414.
12.
Coghlin CL, Smith LJ, Bakar S, et al: Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol 2010;5:448–452.
13.
Edwards SL, Roberts C, McKean ME, et al: Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000;53:537–540.
14.
Ocque R, Tochiqi N, Paul Ohori N, Dacic S: Usefullness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. Am J Clin Pathol 2011;136:81–87.
15.
Liu J, Farhood A: Immunostaining for thyroid transcription factor-1 on fine needle aspiration specimens of lung tumors. Cancer Cytopathol 2004;102:109–114.
16.
Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010;41:20–25.
17.
Kim JH, Kim YS, Choi YD, et al: Utility of napsin a and thyroid transcription factor 1 in differentiating metastatic pulmonary from non-pulmonary adenocarcinoma in pleural effusion. Acta Cytologica 2011;55:266–270.
18.
Ordonez NG: Napsin A expression in lung and kidney neoplasia: a review and update. Adv Anat Pathol 2012;19:66–73.
19.
Matoso A, Singh K, Jacob R, et al: Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 2010;18:142–149.
20.
Penman D, Downie I, Roberts F: Positive immunostaining for thyroid transcription factor-1 in primary and metastatic colonic adenocarcinoma: a note of caution. J Clin Pathol 2006;59:663–664.
21.
Comperat E, Zhang F, Perrotin C, et al: Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. Mod Pathol 2005;18:1371–1376.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.